Hikma Pharmaceuticals (HIK) Downgraded by Numis Securities

Hikma Pharmaceuticals (LON:HIK) was downgraded by Numis Securities to an “add” rating in a research report issued on Friday. They currently have a GBX 1,560 ($21.16) target price on the stock, up from their previous target price of GBX 1,300 ($17.63). Numis Securities’ price target indicates a potential upside of 12.64% from the company’s previous close.

A number of other research analysts have also weighed in on the company. Peel Hunt reissued a “hold” rating and issued a GBX 1,390 ($18.86) price objective on shares of Hikma Pharmaceuticals in a report on Thursday, February 1st. Barclays lowered Hikma Pharmaceuticals to an “underweight” rating and cut their price objective for the company from GBX 1,500 ($20.35) to GBX 800 ($10.85) in a report on Thursday, March 1st. Citigroup raised Hikma Pharmaceuticals to a “buy” rating and set a GBX 1,250 ($16.96) price objective on the stock in a report on Thursday, March 15th. Jefferies Group raised Hikma Pharmaceuticals to a “hold” rating and increased their price objective for the company from GBX 895 ($12.14) to GBX 997 ($13.52) in a report on Thursday, March 15th. Finally, Morgan Stanley increased their price objective on Hikma Pharmaceuticals from GBX 1,000 ($13.56) to GBX 1,050 ($14.24) and gave the company an “equal weight” rating in a report on Thursday, March 15th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of GBX 1,131.70 ($15.35).

Shares of Hikma Pharmaceuticals opened at GBX 1,385 ($18.79) on Friday, MarketBeat Ratings reports. Hikma Pharmaceuticals has a fifty-two week low of GBX 814.20 ($11.04) and a fifty-two week high of GBX 2,346 ($31.82).

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit